Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
18.31
-0.10 (-0.54%)
Jun 18, 2026, 4:00 PM EDT - Market closed
Monte Rosa Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 159.86 | 129.88 | 224.25 | 128.1 | 54.91 | 346.07 |
Short-Term Investments | 506.36 | 247.22 | 147.9 | 104.31 | 207.91 | - |
Cash & Short-Term Investments | 666.22 | 377.1 | 372.15 | 232.41 | 262.83 | 346.07 |
Cash Growth | 104.32% | 1.33% | 60.12% | -11.57% | -24.05% | 729.93% |
Accounts Receivable | - | 7 | - | - | - | - |
Other Receivables | 4.61 | 4.6 | 0.17 | 0.51 | 7.66 | - |
Total Trade Receivables | 4.61 | 11.6 | 0.17 | 0.51 | 7.66 | - |
Other Current Assets | 6.72 | 4.48 | 5.12 | 3.29 | 5.4 | 2.6 |
Total Current Assets | 677.55 | 393.19 | 377.44 | 236.21 | 275.89 | 348.67 |
Net Property, Plant & Equipment | 53.1 | 50.37 | 56.31 | 62.61 | 61.91 | 12.33 |
Other Long-Term Assets | 5.78 | 5.1 | 4.98 | 4.93 | 4.6 | 5.34 |
Total Assets | 736.43 | 448.66 | 438.73 | 303.76 | 342.39 | 366.33 |
Accounts Payable | 7.9 | 3.55 | 17.22 | 11.15 | 7.86 | 6.56 |
Accrued Expenses | 25.59 | 26.69 | 18.79 | 14.6 | 14.58 | 10.08 |
Current Portion of Leases | 4.48 | 4.4 | 3.71 | 3.16 | 3.13 | - |
Unearned Revenue | 33.06 | 29.57 | 117.23 | 17.68 | - | - |
Total Current Liabilities | 71.04 | 64.21 | 156.95 | 46.59 | 25.57 | 16.64 |
Long-Term Leases | 34.58 | 34.79 | 39 | 42.88 | 43.87 | - |
Other Long-Term Liabilities | 108.9 | 116.6 | 19.85 | 35.04 | 1.53 | 2.18 |
Total Long-Term Liabilities | 143.48 | 151.39 | 58.85 | 77.91 | 45.41 | 2.18 |
Total Liabilities | 214.51 | 215.6 | 215.8 | 124.51 | 70.98 | 18.81 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.01 |
Additional Paid-in Capital | 1,048 | 714.09 | 664.87 | 547.86 | 503.7 | 471.57 |
Accumulated Other Comprehensive Income | -4.75 | -3.83 | -3.36 | -2.72 | -1.75 | -2.02 |
Retained Earnings | -521.72 | -477.21 | -438.59 | -365.89 | -230.54 | -122.04 |
Total Common Shareholders' Equity | 521.92 | 233.06 | 222.94 | 179.25 | 271.41 | 347.52 |
Shareholders' Equity | 521.92 | 233.06 | 222.94 | 179.25 | 271.41 | 347.52 |
Total Liabilities & Equity | 736.43 | 448.66 | 438.73 | 303.76 | 342.39 | 366.33 |
Total Debt | 39.06 | 39.19 | 42.72 | 46.04 | 47 | 0 |
Net Cash (Debt) | 627.16 | 337.91 | 329.43 | 186.37 | 215.83 | 346.07 |
Net Cash Growth | 85.60% | 2.57% | 76.76% | -13.65% | -37.64% | 729.93% |
Net Cash Per Share | 7.21 | 4.07 | 4.46 | 3.63 | 4.57 | 13.84 |
Book Value | 521.92 | 233.06 | 222.94 | 179.25 | 271.41 | 347.52 |
Book Value Per Share | 6.00 | 2.81 | 3.02 | 3.49 | 5.75 | 13.90 |
Tangible Book Value | 521.92 | 233.06 | 222.94 | 179.25 | 271.41 | 347.52 |
Tangible Book Value Per Share | 6.00 | 2.81 | 3.02 | 3.49 | 5.75 | 13.90 |